Hun-Jun Park

Prof. Dr. Hun-Jun Park

Division of Cardiology, Seoul St. Mary's Hospital, The Catholic University of Korea
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
SPSoon-Jung Park
Soon-Jung Park
RKRi Youn Kim
Ri Youn Kim
BPBONG-WOO PARK
BONG-WOO PARK
SLSunghun Lee
Sunghun Lee
SCSeong Woo Choi
Seong Woo Choi
HPHun-Jun Park
Hun-Jun Park
Since both myocardium and vasculature in the heart are excessively damaged following myocardial infarction (MI), therapeutic strategies for treating MI hearts should concurrently target both so as to achieve true cardiac repair. Here we demonstrate a concomitant method that exploits the advantages of cardiomyocytes derived from human induced pluripotent stem cells (hiPSC-CMs) and human mesenchymal stem cell-loaded patch (hMSC-PA) to amplify cardiac repair in a rat MI model. Epicardially implanted hMSC-PA provide a complimentary microenvironment which enhances vascular regeneration through prolonged secretion of paracrine factors, but more importantly it significantly improves the retention and engraftment of intramyocardially injected hiPSC-CMs which ultimately restore the cardiac function. Notably, the majority of injected hiPSC-CMs display adult CMs like morphology suggesting that the secretomic milieu of hMSC-PA constitutes pleiotropic effects in vivo. We provide compelling evidence that this dual approach can be a promising means to enhance cardiac repair on MI hearts.

1 May 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
JLJu-Ro Lee
Ju-Ro Lee
BPBONG-WOO PARK
BONG-WOO PARK
JKJonghoon Kim
Jonghoon Kim
YCYeon Woong Choo
Yeon Woong Choo
Han Young KimHan Young Kim
Han Young Kim
BKByung-Soo Kim
Byung-Soo Kim
Increased therapeutic factors and retention of IONP-NVs substantially enhance therapeutic potential for cardiac repair.

22 October 2019 in Applied Physics Reviews
Verified
Journal Article
Closed access
PDF file
Ge GaoGe Gao
Ge Gao
HKHyeok Kim
Hyeok Kim
BKByoung Soo Kim
Byoung Soo Kim
JKJeong Sik Kong
Jeong Sik Kong
JLJae Yeon Lee
Jae Yeon Lee
Dong-Woo ChoDong-Woo Cho
Dong-Woo Cho
Tissue engineering has emerged as a promising approach to viable small-diameter vascular grafts that may be used to treat cardiovascular diseases. One challenge in constructing such blood vessels is proper localization of endothelial cells and smooth muscle cells, as well as promotion of their cellular functions to generate functional tissues. Thus far, construction of small-diameter vascular substitutes with both endothelial and muscular tissues, which is essential for the grafts to acquire antithrombosis function and sufficient strength to avoid thrombus formation as well as to withstand blood pressure, has not yet been demonstrated. In this study, we engineer small-diameter blood vessel grafts containing both functional endothelial and muscular cell layers, which has been demonstrated in vivo in a living rat model. Our construction of the blood vessel grafts uses vascular-tissue-derived extracellular matrix bioinks and a reservoir-assisted triple-coaxial cell printing technique. The prematured vessel was implanted for three weeks as a graft of rat abdominal aorta in a proof-of-concept study where all implants showed great patency, intact endothelium, remodeled smooth muscle, and integration with host tissues at the end of the study. These outcomes suggest that our approach to tissue-engineered biomimetic blood vessels provides a promising route for the construction of durable small-diameter vascular grafts that may be used in future treatments of cardiovascular diseases.

27 March 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
BPBONG-WOO PARK
BONG-WOO PARK
SJSoo-Hyun Jung
Soo-Hyun Jung
SDSanskrita Das
Sanskrita Das
SLSoon Min Lee
Soon Min Lee
JPJae-Hyun Park
Jae-Hyun Park
HPHun-Jun Park
Hun-Jun Park
Priming human BM-MSCs with engineered HGF-MSCs in vivo significantly improves therapeutic potential for myocardial infarction.

22 March 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
SMSungjin Min
Sungjin Min
SKSuran Kim
Suran Kim
WSwoo-sup sim
woo-sup sim
YCYi Sun Choi
Yi Sun Choi
HJHyebin Joo
Hyebin Joo
SCSeung-Woo Cho
Seung-Woo Cho
Engineered human cardiac tissues have been utilized for various biomedical applications, including drug testing, disease modeling, and regenerative medicine. However, the applications of cardiac tissues derived from human pluripotent stem cells are often limited due to their immaturity and lack of functionality. Therefore, in this study, we establish a perfusable culture system based on in vivo-like heart microenvironments to improve human cardiac tissue fabrication. The integrated culture platform of a microfluidic chip and a three-dimensional heart extracellular matrix enhances human cardiac tissue development and their structural and functional maturation. These tissues are comprised of cardiovascular lineage cells, including cardiomyocytes and cardiac fibroblasts derived from human induced pluripotent stem cells, as well as vascular endothelial cells. The resultant macroscale human cardiac tissues exhibit improved efficacy in drug testing (small molecules with various levels of arrhythmia risk), disease modeling (Long QT Syndrome and cardiac fibrosis), and regenerative therapy (myocardial infarction treatment). Therefore, our culture system can serve as a highly effective tissue-engineering platform to provide human cardiac tissues for versatile biomedical applications.

1 October 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
CKCheesue Kim
Cheesue Kim
HKHyeok Kim
Hyeok Kim
WSwoo-sup sim
woo-sup sim
MJMungyo Jung
Mungyo Jung
JHJihye Hong
Jihye Hong
BKByung-Soo Kim
Byung-Soo Kim
Neutrophils are critical mediators of both the initiation and resolution of inflammation after myocardial infarction (MI). Overexuberant neutrophil signaling after MI exacerbates cardiomyocyte apoptosis and cardiac remodeling while neutrophil apoptosis at the injury site promotes macrophage polarization toward a pro-resolving phenotype. Here, we describe a nanoparticle that provides spatiotemporal control over neutrophil fate to both stymie MI pathogenesis and promote healing. Intravenous injection of roscovitine/catalase-loaded poly(lactic-co-glycolic acid) nanoparticles after MI leads to nanoparticle uptake by circulating neutrophils migrating to the infarcted heart. Activated neutrophils at the infarcted heart generate reactive oxygen species, triggering intracellular release of roscovitine, a cyclin-dependent kinase inhibitor, from the nanoparticles, thereby inducing neutrophil apoptosis. Timely apoptosis of activated neutrophils at the infarcted heart limits neutrophil-driven inflammation, promotes macrophage polarization toward a pro-resolving phenotype, and preserves heart function. Modulating neutrophil fate to tune both inflammatory and reparatory processes may be an effective strategy to treat MI.